Table 1.
Demographics and Clinical Characteristics at Study Entry Among 3532 Patients Who Entered Care With a CD4 Cell Count >500 cells/mm3 Between 1 January 1998 and 31 December 2013 at 8 US Clinical Sites, Followed for Death for Up to 10 Years
| Characteristic | All Patients at Study Entry (n = 3532) | 18–34 Years of Age at Study Entry (n = 1744) | 35–44 Years of Age at Study Entry (n = 1132) | 45–65 Years of Age at Study Entry (n = 627) |
|---|---|---|---|---|
| n (%) | % | % | % | |
| Male | 2886 (82.1) | 83.8 | 81.3 | 78.9 |
| Black | 1194 (34.0) | 32.7 | 33.0 | 38.9 |
| Hispanic ethnicity | 329 (9.4) | 11.6 | 7.8 | 6.2 |
| Injection drug user | 581 (16.5) | 12.3 | 20.2 | 21.9 |
| Men who have sex with men | 2359 (67.1) | 73.8 | 64.2 | 54.5 |
| AIDS | 189 (5.4) | 3.6 | 6.3 | 8.6 |
| CD4 cell count at entry, cells/mm3 | ||||
| 500–600 | 1292 (36.8) | 37.2 | 35.0 | 38.6 |
| 601–750 | 1180 (33.8) | 33.4 | 34.3 | 32.5 |
| 751–1000 | 786 (22.5) | 22.3 | 23.6 | 20.4 |
| >1000 | 257 (7.31) | 7.1 | 7.2 | 8.5 |
| CD4 cell count at initiation of ART, cells/mm3 | ||||
| 0–200 | 92 (2.6) | 1.9 | 3.3 | 3.2 |
| 201–350 | 293 (8.3) | 6.2 | 10.8 | 10.0 |
| 351–500 | 374 (10.6) | 10.3 | 10.4 | 11.5 |
| >500 | 1052 (29.9) | 30.8 | 26.5 | 33.8 |
| Did not initiate ART while in the study | 1704 (48.5) | 50.1 | 49.0 | 41.5 |
| Year at study entry | ||||
| 1998–2002 | 1013 (28.8) | 25.7 | 35.8 | 25.0 |
| 2003–2007 | 1154 (32.8) | 30.7 | 36.1 | 32.5 |
| 2008–2013 | 1348 (38.3) | 43.6 | 28.1 | 42.4 |
Abbreviation: ART, antiretroviral therapy.